20240024443. AUGMENTATION OF SURVIVIN MODIFIED MRNA VACCINE EFFICACY USING DENDRITIC CELLS simplified abstract (Regen Biopharma, Inc.)
AUGMENTATION OF SURVIVIN MODIFIED MRNA VACCINE EFFICACY USING DENDRITIC CELLS
Organization Name
Inventor(s)
Thomas Ichim of San Diego CA (US)
AUGMENTATION OF SURVIVIN MODIFIED MRNA VACCINE EFFICACY USING DENDRITIC CELLS - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240024443 titled 'AUGMENTATION OF SURVIVIN MODIFIED MRNA VACCINE EFFICACY USING DENDRITIC CELLS
Simplified Explanation
The patent application describes methods and compositions for stimulating immunity towards cancer using dendritic cells that have been stimulated and/or incorporated with mRNA encoding survivin and/or related gene sequences. The dendritic cells can be generated from allogeneic sources and transfected with survivin modified mRNA, which are then administered in an immunogenic manner. In some embodiments, the transfected dendritic cells undergo immunogenic cell death ex vivo before being used as immunogenic stimuli. In other embodiments, the injection site is prepared by pre-administration of agents that increase the number of local dendritic cells in the skin before the administration of transfected dendritic cells. In vivo transfection of survivin modified mRNA can be achieved by administering dendritic cell accumulating agents followed by in vivo transfection.
- Dendritic cells are stimulated and/or incorporated with mRNA encoding survivin and/or related gene sequences.
- Allogeneic dendritic cells are transfected with survivin modified mRNA and administered in an immunogenic manner.
- Transfected dendritic cells can undergo immunogenic cell death ex vivo and used as immunogenic stimuli.
- Preparation of the injection site can be performed by pre-administration of agents that increase the number of local dendritic cells in the skin.
- In vivo transfection of survivin modified mRNA can be achieved by administering dendritic cell accumulating agents followed by in vivo transfection.
Potential applications of this technology: - Cancer immunotherapy: The stimulation of immunity towards cancer using dendritic cells and survivin modified mRNA can potentially be used as a treatment for various types of cancer. - Personalized medicine: The ability to generate dendritic cells from allogeneic sources and modify them with specific mRNA sequences allows for personalized immunotherapy approaches tailored to individual patients.
Problems solved by this technology: - Limited effectiveness of current cancer treatments: This technology offers a novel approach to stimulate the immune system and enhance the body's ability to fight cancer, potentially overcoming limitations of traditional cancer treatments. - Lack of personalized cancer therapies: By utilizing dendritic cells and mRNA encoding specific gene sequences, this technology enables the development of personalized cancer immunotherapies that target individual patients' unique cancer profiles.
Benefits of this technology: - Enhanced immune response: The stimulation of immunity towards cancer using dendritic cells and survivin modified mRNA can lead to a stronger and more targeted immune response against cancer cells. - Potential for improved treatment outcomes: By harnessing the power of the immune system, this technology has the potential to improve treatment outcomes and increase survival rates for cancer patients. - Personalized approach: The ability to modify dendritic cells with specific mRNA sequences allows for personalized cancer immunotherapies that can target the specific genetic characteristics of individual patients' tumors.
Original Abstract Submitted
disclosed are methods, and compositions useful for stimulation of immunity towards cancer by utilizing dendritic cells and products therefrom that have been stimulated and/or incorporated mrna encoding survivin and/or related gene sequences, defined herein as “survivin modified mrna”. in one embodiment dendritic cells generated from allogeneic “off the shelf” sources are transfected with survivin modified mrna and the cells are administered in an immunogenic manner. in some embodiments transfected dendritic cells are induced to undergo immunogenic cell death ex vivo subsequently to which they are used as immunogenic stimuli. in other embodiments preparation of the injection site is performed prior to administration of dendritic cells that have been transfected with survivin modified mrna by pre-administration of agents increasing the number of local dendritic cells in the skin. in embodiments in vivo, transfection of survivin modified mrna is performed by administration of dendritic cell accumulating agents followed by in vivo transfection.
